

## IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Ezio BOMBARDELLI

Conf.

Application No. NEW NATIONAL PHASE

Group

Filed December 23, 2005

Examiner

COMBINATIONS OF VASOPROTECTIVE AGENTS AND FORMULATIONS CONTAINING THEM

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION CONCURRENT WITH THE  
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 23, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☒ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☐ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

IAPO Rec'd PCT/PTO 23 DEC 2009

a. ☐ DOCUMENTS IN THE ENGLISH LANGUAGE

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ FOREIGN SEARCH REPORT OR ACTION

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ OTHER

The following additional information is provided for the Examiner's consideration.

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel, Reg. No. 35,041  
745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297  
Telefax (703) 685-0573  
(703) 979-4709

BC/yr

Enclosures: ☒ Form PTO-1449(s)  
☒ Documents  
☒ Foreign Search Report  
☐ Other: \_\_\_\_\_

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

Attorney Docket No.:

**2503-1185**

Application No.:

**NEW NATIONAL PHASE**

Applicant:

**Ezio BOMBARDELLI**

Filing Date:

**December 23, 2005**

Group Art Unit:

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)
	5,846,569	12/8/1998	ANDERSON et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 99/48386	9/30/1999	INTERNATIONAL				
	WO 00/66078	11/9/2000	INTERNATIONAL				
	WO 98/33494	8/6/1998	INTERNATIONAL				
	0 659 402	6/28/1995	EUROPE				
	0 818 225	1/14/1998	EUROPE				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

PONS P ET AL: "EFFECTS OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE OF PATIENTS WITH TYPE II HYPERCHOLESTEROLAEMIA AND TOLERABILITY TO TREATMENT", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, BIOSCENCE EDIPRINT, GENEVA,, CH, vol. 14, no. 1, 1994, pages 27-33, XP00095179, ISSN: 0251-1649, cited in the application, page 27, lparagraphs 1,2

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* English language abstract provided for the Examiner's convenience

yr